| 1. |
申杰, 趙國偉. 阿布昔替尼治療局限性硬皮病[J]. 臨床皮膚科雜志, 2024, 53(12): 734-736. DOI: 10.16761/j.cnki.1000-4963.2024.12.008.Shen J, Zhao GW. Localized scleroderma successfully treated with abrocitinib: a case report[J]. J Clin Dermatol, 2024, 53(12): 734-736. DOI: 10.16761/j.cnki.1000-4963.2024.12.008.
|
| 2. |
Zhao M, Wu J, Wu H, et al. Clinical treatment options in scleroderma: recommendations and comprehensive review[J]. Clin Rev Allergy Immunol, 2022, 62(2): 273-291. DOI: 10.1007/s12016-020-08831-4.
|
| 3. |
Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis[J]. Pediatr Clin North Am, 2018, 65(4): 757-781. DOI: 10.1016/j.pcl.2018.04.002.
|
| 4. |
Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of pediatric localized scleroderma[J/OL]. Front Immunol, 2019, 10: 908[2019-03-30]. https://pubmed.ncbi.nlm.nih.gov/31114575/. DOI: 10.3389/fimmu.2019.00908.
|
| 5. |
羅鴦鴦, 曾迎紅, 肖嶸, 等. 兒童局限性硬皮病的臨床研究進展[J]. 實用皮膚病學雜志, 2022, 15(6): 360-363. DOI: 10.11786/sypfbxzz.1674-1293.20220610.Luo YY, Zeng YH, Xiao R, et al. Advances of clinical research on juvenile localized scleroderma[J]. Journal of Practical Dermatology, 2022, 15(6): 360-363. DOI: 10.11786/sypfbxzz.1674-1293.20220610.
|
| 6. |
Szucs G, Szekanecz Z, Aszalos Z, et al. A wide spectrum of ocular manifestations signify patients with systemic sclerosis[J]. Ocul Immunol Inflamm, 2021, 29(1): 81-89. DOI: 10.1080/09273948.2019.1657467.
|
| 7. |
Behboudi H, Zayeni H, Haji-Abbasi A, et al. Coats'-like response associated with linear scleroderma[J]. J Ophthalmic Vis Res, 2022, 17(1): 135-139. DOI: 10.18502/jovr.v17i1.10179.
|
| 8. |
Zannin ME, Martini G, Athreya BH, et al. Ocular involvement in children with localised scleroderma: a multi-centre study[J]. Br J Ophthalmol, 2007, 91(10): 1311-1314. DOI: 10.1136/bjo.2007.116038.
|
| 9. |
Mirizio E, Marathi A, Hershey N, et al. Identifying the signature immune phenotypes present in pediatric localized scleroderma[J]. J Invest Dermatol, 2019, 139(3): 715-718. DOI: 10.1016/j.jid.2018.09.025.
|
| 10. |
Fleming JN, Nash RA, Mahoney WM Jr, et al. Is scleroderma a vasculopathy?[J]. Curr Rheumatol Rep, 2009, 11(2): 103-110. DOI: 10.1007/s11926-009-0015-3.
|
| 11. |
Fledelius HC, Danielsen PL, Ullman S. Ophthalmic findings in linear scleroderma manifesting as facial en coup de sabre[J]. Eye (Lond), 2018, 32(11): 1688-1696. DOI: 10.1038/s41433-018-0137-9.
|
| 12. |
Lenassi E, Vassallo G, Kehdi E, et al. Craniofacial linear scleroderma associated with retinal telangiectasia and exudative retinal detachment[J]. J AAPOS, 2017, 21(3): 251-254. DOI: 10.1016/j.jaapos.2016.12.004.
|
| 13. |
Gass JD, Harbin TS Jr, Del Piero EJ. Exudative stellate neuroretinopathy and Coats' syndrome in patients with progressive hemifacial atrophy[J]. Eur J Ophthalmol, 1991, 1(1): 2-10. DOI: 10.1177/112067219100100102.
|
| 14. |
Liguoro I, Simonini G, Martini G. The burden of extracutaneous manifestations in juvenile localized scleroderma: a literature review[J/OL]. Autoimmun Rev, 2025, 24(7): 103812[2025-04-04]. https://pubmed.ncbi.nlm.nih.gov/40189033/. DOI: 10.1016/j.autrev.2025.103812.
|
